Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2012 1
2013 1
2014 1
2015 2
2017 2
2018 3
2019 4
2020 10
2021 15
2022 9
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Single-cell RNA sequencing identifies a population of human liver-type ILC1s.
Krämer B, Nalin AP, Ma F, Eickhoff S, Lutz P, Leonardelli S, Goeser F, Finnemann C, Hack G, Raabe J, ToVinh M, Ahmad S, Hoffmeister C, Kaiser KM, Manekeller S, Branchi V, Bald T, Hölzel M, Hüneburg R, Nischalke HD, Semaan A, Langhans B, Kaczmarek DJ, Benner B, Lordo MR, Kowalski J, Gerhardt A, Timm J, Toma M, Mohr R, Türler A, Charpentier A, van Bremen T, Feldmann G, Sattler A, Kotsch K, Abdallah AT, Strassburg CP, Spengler U, Carson WE 3rd, Mundy-Bosse BL, Pellegrini M, O'Sullivan TE, Freud AG, Nattermann J. Krämer B, et al. Among authors: mohr r. Cell Rep. 2023 Jan 31;42(1):111937. doi: 10.1016/j.celrep.2022.111937. Epub 2023 Jan 1. Cell Rep. 2023. PMID: 36640314 Free PMC article.
Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L, Knauss S, Ginesta Roque L, Schinke C, Maierhof SK, Bartels F, Finke C, Rentzsch K, Ulrich C, Mohr R, Stenzel W, Endres M, Boehmerle W, Huehnchen P. Müller-Jensen L, et al. Among authors: mohr r. Front Immunol. 2023 Feb 8;14:1108116. doi: 10.3389/fimmu.2023.1108116. eCollection 2023. Front Immunol. 2023. PMID: 36845122 Free PMC article.
The therapeutic landscape of hepatocellular carcinoma.
Gallage S, García-Beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. Gallage S, et al. Among authors: mohr r. Med. 2021 May 14;2(5):505-552. doi: 10.1016/j.medj.2021.03.002. Epub 2021 Apr 27. Med. 2021. PMID: 35590232 Free article. Review.
Immune signatures of checkpoint inhibitor-induced autoimmunity-A focus on neurotoxicity.
Müller-Jensen L, Schulz AR, Mei HE, Mohr R, Ulrich C, Knape P, Frost N, Frischbutter S, Kunkel D, Schinke C, Ginesta Roque L, Maierhof SK, Nickel FT, Heinzerling L, Endres M, Boehmerle W, Huehnchen P, Knauss S. Müller-Jensen L, et al. Among authors: mohr r. Neuro Oncol. 2024 Feb 2;26(2):279-294. doi: 10.1093/neuonc/noad198. Neuro Oncol. 2024. PMID: 37823709
Pulmonary Complications in Patients with Liver Cirrhosis.
Benz F, Mohr R, Tacke F, Roderburg C. Benz F, et al. Among authors: mohr r. J Transl Int Med. 2020 Sep 25;8(3):150-158. doi: 10.2478/jtim-2020-0024. eCollection 2020 Sep. J Transl Int Med. 2020. PMID: 33062591 Free PMC article. Review.
67 results